Evaluation of SHR-1210 in Combination with Apatinib for Treating BRAF-Negative Mucosal Melanoma: Insights on Efficacy, Safety, and Precision Medicine Applications - Quiz - MDSpire

Evaluation of SHR-1210 in Combination with Apatinib for Treating BRAF-Negative Mucosal Melanoma: Insights on Efficacy, Safety, and Precision Medicine Applications

  • By

  • Yong Zhang

  • Ting Wang

  • An-Qi Lyu

  • Fang Zhang

  • Fang-Hui Li

  • Ling-Di Zhao

  • Zi-Bing Wang

  • Yi-Man Shang

  • Bao-Zhen Ma

  • Xiao-Qun Dong

  • Quan-Li Gao

  • April 21, 2026

  • 0 min

Share

Original Source(s)

Evaluation of SHR-1210 in Combination with Apatinib for Treating BRAF-Negative Mucosal Melanoma: Insights on Efficacy, Safety, and Precision Medicine Applications

  • by Yong Zhang, Ting Wang, An-Qi Lyu, Fang Zhang, Fang-Hui Li, Ling-Di Zhao, Zi-Bing Wang, Yi-Man Shang, Bao-Zhen Ma, Xiao-Qun Dong, Quan-Li Gao

  • April 21, 2026

Related Content

Prospective Evidence on Artificial Intelligence−Assisted Melanoma Diagnostics: A Systematic Review and

Errors in the Table 2

  • May 1, 2026

CD38hiCD19dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade